Loading in 2 Seconds...
Loading in 2 Seconds...
Exploring the Structural Changes in the Global Pharmaceutical Marketplace. Dr. Brian W Tempest www.briantempest.com 9 th Annual Global Generic Strategy Summit Barcelona, Spain 14-16September 2010.
Dr. Brian W Tempest
9th Annual Global Generic Strategy Summit
Barcelona, Spain 14-16September 2010
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade.
Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo where he was responsible for businesses in Japan, China, Korea, and Taiwan.
Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE – India, Religare -India and UNCTAD - Switzerland. In addition he is a member of the SCRIP Global awards panel. Brian speaks at global conferences on the Challenge from India and China and more information on these presentations can be found on his website www.briantempest.com.
Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman of Hale & Tempest Co Ltd.
Economic Health in 2009
The Future? - Pharma Vending Machines currently being test marketed in UK Hospitals & Supermarkets 2010
NCE Productivity continues to fall
Approvals becoming Difficult Source: Pharmatimes UK July-August 2010
Many Drugs withdrawn this Decade Source: Deutsche bank, FDA
USA – Many OTC Switches this Decade Source: Deutsche Bank
82% of the world population accounts for only 12% of the global pharma sales
Source EIU, OECD, WHO, IMS, Roland Berger
Abbott now has 7000 reps & 7% Market Share
with New Alliances
USA Generics Filings Source: Deutsche bank July 2010
USA Challenge – Size of Product Basket Source: Deutsche Bank
Generic Profit Margin Profile in descending order source: Deutsche Bank July 2010
Top 22 Generic Companies over $1b Source: Company Reports Generics Bulletin 28 May 2010 (excludes Apotex & Actavis Private Companies)
Next18 Generic Companies < $1b Source: Company Reports Generics Bulletin 28 May 2010 (excludes Recalcine Private Company)
Indian Pharma Companies
outperformed USA Generics
Indian Deals Roaring Ahead July 2010 Grant Thornton Deal Tracker
Early discovery leads from US, Europe, Taiwan, Singapore
Molecular optimisation from India
Toxicology from China, Central Europe, Singapore
Electronic Data Capture from India
API Manufacture from India with Raw Materials from China
Drug Formulation Manufacture from India, USA
Phase 1 Clinical Trials from Europe
Phase 2,3 heavy use of India
Corporate back office from India